PV QA 4 - Poster Viewing Q&A 4
Purpose/Objective(s): To estimate the prognostic role of plasmatic levels of IL-13 in patients with early stage non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiation therapy (SABR).
Materials/Methods: Fifteen patients were prospectively enrolled in this pilot study from January 2010 to December 2012. Blood samples were collected at the following time: first day of SABR (TFd), last day of SABR (TLd) and 45 days (T45d) after the end of SABR. Firstly, we aimed to investigate whether IL-13 levels were associated with cancer specific survivals (CSS). Secondly, we tested if different IL-13 levels might identify specific subgroups of patients at higher risk of radiation-induced lung toxicity.
Results: All patients received a radiation dose prescription of 52 Gy in 8 fractions for stage IA-B NSCLC. IL-13 levels, measured at TFd (p=0.038) and T45d, resulted significantly associated with lower CSS (p=0.045). Additionally, a trend of correlation between IL-13 levels at T45d and late moderate-severe chronic radiological lung injury was also observed (p= 0.06)
Conclusion: The results of this pilot study suggest that IL-13 levels may correlate with lower CSS and a higher incidence of late moderate-severe lung toxicity. A larger sample size is needed to confirm or not this hypothesis.
The asset you are trying to access is locked. Please enter your access key to unlock.